Page last updated: 2024-09-03

gefitinib and sgi 1776

gefitinib has been researched along with sgi 1776 in 3 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(sgi 1776)
Trials
(sgi 1776)
Recent Studies (post-2010) (sgi 1776)
5,2315662,91959056

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)sgi 1776 (IC50)
Tyrosine-protein kinase YesHomo sapiens (human)1.455
Serine/threonine-protein kinase pim-1Homo sapiens (human)0.0158
Delta-type opioid receptorRattus norvegicus (Norway rat)0.007
Mu-type opioid receptorRattus norvegicus (Norway rat)0.362
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0382
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)0.069
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.8727
Serine/threonine-protein kinase pim-3Homo sapiens (human)0.0659
Serine/threonine-protein kinase haspinHomo sapiens (human)0.034
Serine/threonine-protein kinase pim-2Homo sapiens (human)0.4053

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Jongstra, J; Siu, A; Virtanen, C1

Other Studies

3 other study(ies) available for gefitinib and sgi 1776

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
    Oncotarget, 2011, Volume: 2, Issue:12

    Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; MAP Kinase Signaling System; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1; Pyridazines; Quinazolines; RNA Interference; RNA, Small Interfering; Tumor Suppressor Proteins

2011